Professor AlGhananeem is an Academic Leadership Fellow (ALFP) of the American Association of Colleges of Pharmacy (AACP), Past Chair and Commissioner at The Accreditation Council for Pharmacy Education (ACPE) International Services Program, Board of Trustees member at Talal Abu-Ghazaleh University College for Innovation (TAGUCI) Jordan, a Global Lead for Quality Assurance at The International Pharmaceutical Federation (FIP), and Associate Editor of the FIP Pharmacy Education Journal. Prof. AlGhananeem received a Bachelor of Science in Pharmacy degree from the University of Jordan and her Master’s and Doctor of Philosophy degrees from the University of Kentucky, College of Pharmacy. Prior to Joining AU, Prof AlGhananeem was the Associate Dean of Research at Sullivan University College of Pharmacy and Health Sciences. She also held a faculty appointment at the University of Kentucky College of Pharmacy, which is ranked among the top ten colleges of pharmacy in USA. She also served at national and international initiatives and innovative projects that connect science with global health matters, such as the United States Agency for International Development (USAID) in Jordan as a steering committee member for Continuous professional development (CPD) and inter-professional education (IPE) in health sciences. Furthermore, Prof. AlGhananeem has a successful academicindustrial research collaboration initiatives that culminate into several USA FDA approved drugs such as Revonto™ injection, Lucemyra™ tablets, Subsys™ sublingual spray, Valchor gel, and several dietary supplement products such as Luciplex, Noctoplex, Addivance, Calmposure, and GoodSprouts topical pediatrics products and cosmetic pharmaceutical preparations.
Prof. AlGhananeem has been involved in successful academic-industrial research collaboration initiatives that culminated in several USA FDA-approved drugs, including Revonto™ injection, Lucemyra™ tablets, Subsys™ sublingual spray, Valchor gel, and several dietary supplement products such as Luciplex, Noctoplex, Addivance, Calmposure, and GoodSprouts topical pediatric products, as well as cosmetic pharmaceutical preparations.
Unlocking Efficiency: Pharmaco-Scintigraphy for Streamlining Bioequivalence of GI-Targeted Delayed-Release Formulations Drugs
Establishing bioequivalence (BE) for locally acting drugs targeting specific regions within the gastrointestinal (GI) tract presents considerable challenges, particularly when dealing with delayed-release formulations and the inherent variability associated with these drugs. Pharmaco-scintigraphy, a dynamic imaging technique, offers real-time visualization of drug release, transit, and action within the GI tract, providing a valuable tool for advancing drug development. This technology enables the tracking of drug behavior without the need for extensive and costly clinical trials, potentially streamlining the development process. Pharmaco-scintigraphy was employed to assess test formulation against a reference formulation prior to undertaking traditional BE studies. The results streamlined the selection process and facilitated the choice of the test formulation that exhibited similar pharmacokinetic profiles to the reference formulation, with comparable variability in critical parameters such as maximum concentration and area under the curve. Importantly, scintigraphy provided valuable insights into tablet disintegration and drug absorption, which were corroborated by stool analysis, contributing to the optimization of the test formulation. These findings highlight the potential of pharmaco-scintigraphy to not only enhance the efficiency of bioequivalence evaluations but also improve the precision of drug delivery, ultimately improving patient outcomes and accelerating the development of GI-targeted therapies.